Inosine acedoben dimepranol
- Drugs List
- Therapeutic Indications
- Precautions and Warnings
- Pregnancy and Lactation
- Side Effects
Management of mucocutaneous infections due to herpes simplex virus (HSV-1 or HSV-2)
Management of genital warts (adjunctive treatment to podophyllin or carbon dioxide laser)
Management of subacute sclerosing panencephalitis (SSPE)
Mucocutaneous herpes simplex
1g to be taken 4 times a day for 7 to 14 days.
Genital warts (as adjunctive therapy to podophyllin or carbon dioxide laser treatment)
1g to be taken 3 times a day for 14 to 28 days.
Subacute sclerosing panencephalitis (SSPE)
50 to 100mg/kg daily, to be taken in 6 divided doses.
Patients with Renal Impairment
Caution is recommended as inosine acedoben dimepranol is metabolised to uric acid.
Pregnancy - see Pregnancy section
Breastfeeding - see Lactation section.
Children under 18 years old
Precautions and Warnings
Inosine is metabolised to uric acid and should be used with caution in patients with the following conditions:
History of gout
Pregnancy and Lactation
Inosine acedoben dimepranol should be avoided where pregnancy is suspected or confirmed.
There are no data, at the time of writing, on the use of inosine acedoben dimepranol during human pregnancy.
Animal tests have shown no teratogenic effect.
The use of all medication in pregnancy should be avoided whenever possible; particularly in the first trimester. Non-drug treatments should also be considered. When essential, a medication with the best safety record over time should be chosen, employing the lowest effective dose for the shortest possible time. Polypharmacy should be avoided. Teratogens taken in the pre-embryonic period, often quoted as lasting until 14-17 days post-conception, are believed to have an all-or-nothing effect. Where drugs have a short half-life, and when the date of conception is certain, this may allow women to be reassured where drug exposure has occurred within this time frame. Further advice may be available from the UK National Teratology Information Service (NTIS) and through ToxBase, available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Inosine should not be administered during lactation unless the physician decides that the benefits of therapy outweigh the potential risks.
It is not known if inosine is excreted in human milk.
Neonates, infants born prematurely, those with low birth weight, those with an unstable gastrointestinal function or who have serious illnesses may require special consideration. For any infant, if a drug is prescribed to the nursing mother, it should be at the lowest practical dose and for the shortest time. When drug administration is unavoidable and breastfeeding is to continue, minimisation of exposure of the infant to the drug may sometimes be achieved by timing the maternal doses to just after a feeding episode. Infants exposed to drugs via breast milk should be monitored for unusual signs or symptoms. Interactions between the drug received by the infant from the mother's milk and medication prescribed for the infant should also be considered, for example, when the drug given to the infant may prevent metabolism of the drug received via breast milk.
Specialist advice is available from the UK Drugs in Lactation Advisory Service at https://www.midlandsmedicines.nhs.uk/content.asp?section=6&subsection=17&pageIdx=1
Effects on Ability to Drive and Operate Machinery
There are no effects on the ability to drive or operate machinery.
Increase of liver transaminases
Increase in alkaline phosphatase
Increase in blood urea nitrogen
It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.
The following number will direct the caller to the relevant local centre (0844) 892 0111
Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).
Shelf Life and Storage
No special requirements
British National Formulary, 63rd Edition (2012) Pharmaceutical Press, London.
Drugs During Pregnancy and Lactation: Treatment Options and Risk Assessment, 2nd edition (2007) ed. Schaefer, C., Peters, P. and Miller, R. Elsevier, London.
Summary of Product Characteristics: Imunovir. Newport Pharmaceuticals Limited. Revised January 2011.
Already a member? Log in
Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content
FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.